Suppression of APOBEC3-mediated restriction of HIV-1 by Vif

Frontiers in Microbiology

Volumn 5, Issue AUG, 2014, Pages

  Feng, Yuqing ^a   Baig, Tayyba T ^a   Love, Robin P ^a   Chelico, Linda ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

APOBEC3; Deaminase; HIV; Mutagenesis; Restriction factor; Ubiquitination; Vif

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3D; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3H; DEOXYCYTIDINE; HYDROLASE; PROTEASOME; UNCLASSIFIED DRUG; VIF PROTEIN;

ANTIVIRAL ACTIVITY; DEAMINATION; DNA REPAIR; ENZYME ACTIVITY; ENZYME DEGRADATION; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTAGENESIS; REVIEW; RNA TRANSCRIPTION; VIRUS REPLICATION;

EID: 84987850271     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2014.00450     Document Type: Review

References (252)

1. Abdel-Mohsen, M., Raposo, R. A., Deng, X., Li, M., Liegler, T., Sinclair, E., et al. (2013). Expression profile of host restriction factors in HIV-1 elite controllers. Retrovirology 10, 106. doi: 10.1186/1742-4690-10-106
2. Adolph, M. B., Webb, J., and Chelico, L. (2013). Retroviral restriction factor APOBEC3G delays the initiation of DNA synthesis by HIV-1 reverse transcriptase. PLoS ONE 8:e64196. doi: 10.1371/journal.pone.0064196
3. Albin, J. S., Anderson, J. S., Johnson, J. R., Harjes, E., Matsuo, H., Krogan, N. J., et al. (2013). Dispersed sites of HIV Vif-dependent polyubiquitination in the DNA deaminase APOBEC3F. J. Mol. Biol. 425, 1172-1182. doi: 10.1016/j.jmb.2013.01.010
4. Albin, J. S., Brown, W. L., and Harris, R. S. (2014). Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus. Virology 450-451, 49-54. doi: 10.1016/j.virol.2013.11.041
5. Albin, J. S., Hache, G., Hultquist, J. F., Brown, W. L., and Harris, R. S. (2010a). Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function. J. Virol. 84, 10209-10219. doi: 10.1128/JVI.00632-10
6. Albin, J. S., Larue, R. S., Weaver, J. A., Brown, W. L., Shindo, K., Harjes, E., et al. (2010b). A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif. J. Biol. Chem. 285, 40785-40792. doi: 10.1074/jbc.M110.173161
7. Albin, J. S., and Harris, R. S. (2010). Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev. Mol. Med. 12, e4. doi: 10.1017/S1462399409001343
8. Alce, T. M., and Popik, W. (2004). APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J. Biol. Chem. 279, 34083-34086. doi: 10.1074/jbc.C400235200
9. Ali, A., Wang, J., Nathans, R. S., Cao, H., Sharova, N., Stevenson, M., et al. (2012). Synthesis and structure-activity relationship studies of HIV-1 virion infectivity factor (Vif) inhibitors that block viral replication. ChemMedChem 7, 1217-1229. doi: 10.1002/cmdc.201200079
10. Ara, A., Love, R. P., and Chelico, L. (2014). Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms. PLoS Pathog. 10:e1004024. doi: 10.1371/journal.ppat.1004024
11. Armitage, A. E., Katzourakis, A., De Oliveira, T., Welch, J. J., Belshaw, R., Bishop, K. N., et al. (2008). Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences. J. Virol. 82, 8743-8761. doi: 10.1128/JVI.00584-08
12. Aydin, H., Taylor, M. W., and Lee, J. E. (2014). Structure-guided analysis of the human APOBEC3-HIV restrictome. Structure 22, 668-684. doi: 10.1016/j.str.2014.02.011
13. Bach, D., Peddi, S., Mangeat, B., Lakkaraju, A., Strub, K., and Trono, D. (2008). Characterization of APOBEC3G binding to 7SL RNA. Retrovirology 5, 54. doi: 10.1186/1742-4690-5-54
14. Batisse, J., Guerrero, S., Bernacchi, S., Sleiman, D., Gabus, C., Darlix, J. L., et al. (2012). The role of Vif oligomerization and RNA chaperone activity in HIV-1 replication. Virus Res. 169, 361-376. doi: 10.1016/j.virusres.2012.06.018
15. Belanger, K., Savoie, M., Rosales Gerpe, M. C., Couture, J. F., and Langlois, M. A. (2013). Binding of RNA by APOBEC3G controls deamination-independent restriction of retroviruses. Nucleic Acids Res. 41, 7438-7452. doi: 10.1093/nar/gkt527
16. Berg, O. G., Winter, R. B., and Von Hippel, P. H. (1981). Diffusion-driven mechanisms of protein translocation on nucleic acids. 1. Models and theory. Biochemistry 20, 6929-6948. doi: 10.1021/bi00527a028
17. Berger, G., Durand, S., Fargier, G., Nguyen, X. N., Cordeil, S., Bouaziz, S., et al. (2011). APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. PLoS Pathog. 7:e1002221. doi: 10.1371/journal.ppat.1002221
18. Bergeron, J. R., Huthoff, H., Veselkov, D. A., Beavil, R. L., Simpson, P. J., Matthews, S. J., et al. (2010). The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex. PLoS Pathog. 6:e1000925. doi: 10.1371/journal.ppat.1000925
19. Biasin, M., Piacentini, L., Lo Caputo, S., Kanari, Y., Magri, G., Trabattoni, D., et al. (2007). Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J. Infect. Dis. 195, 960-964. doi: 10.1086/511988
20. Binka, M., Ooms, M., Steward, M., and Simon, V. (2012). The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. J. Virol. 86, 49-59. doi: 10.1128/JVI.06082-11
21. Bishop, K. N., Holmes, R. K., and Malim, M. H. (2006). Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 80, 8450-8458. doi: 10.1128/JVI.00839-06
22. Bishop, K. N., Holmes, R. K., Sheehy, A. M., Davidson, N. O., Cho, S. J., and Malim, M. H. (2004). Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14, 1392-1396. doi: 10.1016/j.cub.2004.06.057
23. Bishop, K. N., Verma, M., Kim, E. Y., Wolinsky, S. M., and Malim, M. H. (2008). APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 4:e1000231. doi: 10.1371/journal.ppat.1000231
24. Blanc, D., Patience, C., Schulz, T. F., Weiss, R., and Spire, B. (1993). Transcomplementation of VIF- HIV-1 mutants in CEM cells suggests that VIF affects late steps of the viral life cycle. Virology 193, 186-192. doi: 10.1006/viro.1993.1114
25. Bogerd, H. P., and Cullen, B. R. (2008). Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation. RNA 14, 1228-1236. doi: 10.1261/rna.964708
26. Bogerd, H. P., Doehle, B. P., Wiegand, H. L., and Cullen, B. R. (2004). A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc. Natl. Acad. Sci. U.S.A. 101, 3770-3774. doi: 10.1073/pnas.0307713101
27. Bogerd, H. P., Wiegand, H. L., Doehle, B. P., and Cullen, B. R. (2007). The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology 364, 486-493. doi: 10.1016/j.virol.2007.03.019
28. Bogerd, H. P., Wiegand, H. L., Doehle, B. P., Lueders, K. K., and Cullen, B. R. (2006). APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res. 34, 89-95. doi: 10.1093/nar/gkj416
29. Bohn, M. F., Shandilya, S. M., Albin, J. S., Kouno, T., Anderson, B. D., Mcdougle, R. M., et al. (2013). Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain. Structure 21, 1042-1050. doi: 10.1016/j.str.2013.04.010
30. Bonvin, M., and Greeve, J. (2007). Effects of point mutations in the cytidine deaminase domains of APOBEC3B on replication and hypermutation of hepatitis B virus in vitro. J. Gen. Virol. 88, 3270-3274. doi: 10.1099/vir.0.83149-0
31. Britan-Rosich, E., Nowarski, R., and Kotler, M. (2011). Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif. J. Mol. Biol. 410, 1065-1076. doi: 10.1016/j.jmb.2011.03.058
32. Browne, E. P., Allers, C., and Landau, N. R. (2009). Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent. Virology 387, 313-321. doi: 10.1016/j.virol.2009.02.026
33. Bulliard, Y., Turelli, P., Rohrig, U. F., Zoete, V., Mangeat, B., Michielin, O., et al. (2009). Functional analysis and structural modeling of human APOBEC3G reveal the role of evolutionarily conserved elements in the inhibition of human immunodeficiency virus type 1 infection and Alu transposition. J. Virol. 83, 12611-12621. doi: 10.1128/JVI.01491-09
34. Burdick, R. C., Hu, W. S., and Pathak, V. K. (2013). Nuclear import of APOBEC3F-labeled HIV-1 preintegration complexes. Proc. Natl. Acad. Sci. U.S.A. 110, E4780-E4789. doi: 10.1073/pnas.1315996110
35. Burnett, A., and Spearman, P. (2007). APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. J. Virol. 81, 5000-5013. doi: 10.1128/JVI.02237-06
36. Byeon, I. J., Ahn, J., Mitra, M., Byeon, C. H., Hercik, K., Hritz, J., et al. (2013). NMR structure of human restriction factor APOBEC3A reveals substrate binding and enzyme specificity. Nat. Commun. 4, 1890. doi: 10.1038/ncomms2883
37. Camaur, D., and Trono, D. (1996). Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J. Virol. 70, 6106-6111.
38. Carpenter, M. A., Rajagurubandara, E., Wijesinghe, P., and Bhagwat, A. S. (2010). Determinants of sequence-specificity within human AID and APOBEC3G. DNA Repair (Amst) 9, 579-587. doi: 10.1016/j.dnarep.2010.02.010
39. Casartelli, N., Guivel-Benhassine, F., Bouziat, R., Brandler, S., Schwartz, O., and Moris, A. (2010). The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells. J. Exp. Med. 207, 39-49. doi: 10.1084/jem.20091933
40. Cen, S., Guo, F., Niu, M., Saadatmand, J., Deflassieux, J., and Kleiman, L. (2004). The interaction between HIV-1 Gag and APOBEC3G. J. Biol. Chem. 279, 33177-33184. doi: 10.1074/jbc.M402062200
41. Cen, S., Peng, Z. G., Li, X. Y., Li, Z. R., Ma, J., Wang, Y. M., et al. (2010). Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G. J. Biol. Chem. 285, 16546-16552. doi: 10.1074/jbc.M109.085308
42. Chaipan, C., Smith, J. L., Hu, W. S., and Pathak, V. K. (2013). APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J. Virol. 87, 444-453. doi: 10.1128/JVI.00676-12
43. Chaurasiya, K. R., Mccauley, M. J., Wang, W., Qualley, D. F., Wu, T., Kitamura, S., et al. (2014). Oligomerization transforms human APOBEC3G from an efficient enzyme to a slowly dissociating nucleic acid-binding protein. Nat. Chem. 6, 28-33. doi: 10.1038/nchem.1795
44. Chelico, L., Pham, P., Calabrese, P., and Goodman, M. F. (2006). APOBEC3G DNA deaminase acts processively 3'→5' on single-stranded DNA. Nat. Struct. Mol. Biol. 13, 392-399. doi: 10.1038/nsmb1086
45. Chelico, L., Pham, P., and Goodman, M. F. (2009). Mechanisms of APOBEC3G-catalyzed processive deamination of deoxycytidine on single-stranded DNA. Nat. Struct. Mol. Biol. 16, 454-455. doi: 10.1038/nsmb0509-454
46. Chelico, L., Prochnow, C., Erie, D. A., Chen, X. S., and Goodman, M. F. (2010). Structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G. J. Biol. Chem. 285, 16195-16205. doi: 10.1074/jbc.M110.107987
47. Chelico, L., Sacho, E. J., Erie, D. A., and Goodman, M. F. (2008). A model for oligomeric regulation of APOBEC3G cytosine deaminase-dependent restriction of HIV. J. Biol. Chem. 283, 13780-13791. doi: 10.1074/jbc.M801004200
48. Chen, G., He, Z., Wang, T., Xu, R., and Yu, X. F. (2009). A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J. Virol. 83, 8674-8682. doi: 10.1128/JVI.00653-09
49. Chiu, Y. L., Witkowska, H. E., Hall, S. C., Santiago, M., Soros, V. B., Esnault, C., et al. (2006). High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc. Natl. Acad. Sci. U.S.A. 103, 15588-15593. doi: 10.1073/pnas.0604524103
50. Coffin, J., Hughes, S., and Varmus, H.(eds). (1997). Retroviruses. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
51. Compton, A. A., and Emerman, M. (2013). Convergence and divergence in the evolution of the APOBEC3G-Vif interaction reveal ancient origins of simian immunodeficiency viruses. PLoS Pathog. 9:e1003135. doi: 10.1371/journal.ppat.1003135
52. Conticello, S. G., Harris, R. S., and Neuberger, M. S. (2003). The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13, 2009-2013. doi: 10.1016/j.cub.2003.10.034
53. Dang, Y., Abudu, A., Son, S., Harjes, E., Spearman, P., Matsuo, H., et al. (2011). Identification of a single amino acid required for APOBEC3 antiretroviral cytidine deaminase activity. J. Virol. 85, 5691-5695. doi: 10.1128/JVI.00243-11
54. Dang, Y., Siew, L. M., Wang, X., Han, Y., Lampen, R., and Zheng, Y. H. (2008). Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J. Biol. Chem. 283, 11606-11614. doi: 10.1074/jbc.M707586200
55. Dang, Y., Wang, X., Esselman, W. J., and Zheng, Y. H. (2006). Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 80, 10522-10533. doi: 10.1128/JVI.01123-06
56. Dang, Y., Wang, X., Zhou, T., York, I. A., and Zheng, Y. H. (2009). Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization. J. Virol. 83, 8544-8552. doi: 10.1128/JVI.00651-09
57. Doehle, B. P., Schafer, A., and Cullen, B. R. (2005). Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339, 281-288. doi: 10.1016/j.virol.2005.06.005
58. Douaisi, M., Dussart, S., Courcoul, M., Bessou, G., Vigne, R., and Decroly, E. (2004). HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles. Biochem. Biophys. Res. Commun. 321, 566-573. doi: 10.1016/j.bbrc.2004.07.005
59. Du, J., Wu, X., Long, F., Wen, J., Hao, W., Chen, R., et al. (2013a). Improvement in efficacy of DNA vaccine encoding HIV-1 Vif by LIGHT gene adjuvant. Viral Immunol. 26, 68-74. doi: 10.1089/vim.2012.0073
60. Du, J., Zhao, K., Rui, Y., Li, P., Zhou, X., Zhang, W., et al. (2013b). Differential requirements for HIV-1 Vif-mediated APOBEC3G degradation and RUNX1-mediated transcription by core binding factor beta. J. Virol. 87, 1906-1911. doi: 10.1128/JVI.02199-12
61. Duggal, N. K., Fu, W., Akey, J. M., and Emerman, M. (2013). Identification and antiviral activity of common polymorphisms in the APOBEC3 locus in human populations. Virology 443, 329-337. doi: 10.1016/j.virol.2013.05.016
62. Duggal, N. K., Malik, H. S., and Emerman, M. (2011). The breadth of antiviral activity of Apobec3DE in chimpanzees has been driven by positive selection. J. Virol. 85, 11361-11371. doi: 10.1128/JVI.05046-11
63. Ejima, T., Hirota, M., Mizukami, T., Otsuka, M., and Fujita, M. (2011). An anti-HIV-1 compound that increases steady-state expression of apoplipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G. Int. J. Mol. Med. 28, 613-616. doi: 10.3892/ijmm.2011.737
64. Esnault, C., Heidmann, O., Delebecque, F., Dewannieux, M., Ribet, D., Hance, A. J., et al. (2005). APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 433, 430-433. doi: 10.1038/nature03238
65. Etienne, L., Hahn, B. H., Sharp, P. M., Matsen, F. A., and Emerman, M. (2013). Gene loss and adaptation to hominids underlie the ancient origin of HIV-1. Cell Host Microbe 14, 85-92. doi: 10.1016/j.chom.2013.06.002
66. Feng, Y., and Chelico, L. (2011). Intensity of deoxycytidine deamination of HIV-1 proviral DNA by the retroviral restriction factor APOBEC3G is mediated by the noncatalytic domain. J. Biol. Chem. 286, 11415-11426. doi: 10.1074/jbc.M110.199604
67. Feng, Y., Love, R. P., and Chelico, L. (2013). HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G. J. Biol. Chem. 288, 6083-6094. doi: 10.1074/jbc.M112.421875
68. Fisher, A. G., Ensoli, B., Ivanoff, L., Chamberlain, M., Petteway, S., Ratner, L., et al. (1987). The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 237, 888-893. doi: 10.1126/science.3497453
69. Fitzgibbon, J. E., Mazar, S., and Dubin, D. T. (1993). A new type of G→A hypermutation affecting human immunodeficiency virus. AIDS Res. Hum. Retroviruses 9, 833-838. doi: 10.1089/aid.1993.9.833
70. Fouchier, R. A., Simon, J. H., Jaffe, A. B., and Malim, M. H. (1996). Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J. Virol. 70, 8263-8269.
71. Fourati, S., Malet, I., Binka, M., Boukobza, S., Wirden, M., Sayon, S., et al. (2010). Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals. AIDS 24, 2313-2321. doi: 10.1097/QAD.0b013e32833e515a
72. Fribourgh, J. L., Nguyen, H. C., Wolfe, L. S., Dewitt, D. C., Zhang, W., Yu, X. F., et al. (2014). Core binding factor beta plays a critical role by facilitating the assembly of the Vif-cullin 5 E3 ubiquitin ligase. J. Virol. 88, 3309-3319. doi: 10.1128/JVI.03824-13
73. Gabuzda, D. H., Lawrence, K., Langhoff, E., Terwilliger, E., Dorfman, T., Haseltine, W. A., et al. (1992). Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J. Virol. 66, 6489-6495.
74. Gallois-Montbrun, S., Holmes, R. K., Swanson, C. M., Fernandez-Ocana, M., Byers, H. L., Ward, M. A., et al. (2008). Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F and APOBEC3G antiviral proteins. J. Virol. 82, 5636-5642. doi: 10.1128/JVI.00287-08
75. Gillick, K., Pollpeter, D., Phalora, P., Kim, E. Y., Wolinsky, S. M., and Malim, M. H. (2013). Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination. J. Virol. 87, 1508-1517. doi: 10.1128/JVI.02587-12
76. Goila-Gaur, R., Khan, M. A., Miyagi, E., Kao, S., Opi, S., Takeuchi, H., et al. (2008). HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes. Virology 372, 136-146. doi: 10.1016/j.virol.2007.10.017
77. Goila-Gaur, R., Khan, M. A., Miyagi, E., Kao, S., and Strebel, K. (2007). Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity. Retrovirology 4, 61. doi: 10.1186/1742-4690-4-61
78. Gourraud, P. A., Karaouni, A., Woo, J. M., Schmidt, T., Oksenberg, J. R., Hecht, F. M., et al. (2011). APOBEC3H haplotypes and HIV-1 pro-viral vif DNA sequence diversity in early untreated human immunodeficiency virus-1 infection. Hum. Immunol. 72, 207-212. doi: 10.1016/j.humimm.2010.12.008
79. Greene, W. C. (2007). A history of AIDS: looking back to see ahead. Eur. J. Immunol. 37(Suppl. 1), S94-S102. doi: 10.1002/eji.200737441
80. Greene, W. C., Debyser, Z., Ikeda, Y., Freed, E. O., Stephens, E., Yonemoto, W., et al. (2008). Novel targets for HIV therapy. Antiviral Res. 80, 251-265. doi: 10.1016/j.antiviral.2008.08.003
81. Guo, F., Cen, S., Niu, M., Saadatmand, J., and Kleiman, L. (2006). Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J. Virol. 80, 11710-11722. doi: 10.1128/JVI.01038-06
82. Guo, F., Cen, S., Niu, M., Yang, Y., Gorelick, R. J., and Kleiman, L. (2007). The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J. Virol. 81, 11322-11331. doi: 10.1128/JVI.00162-07
83. Guo, Y., Dong, L., Qiu, X., Wang, Y., Zhang, B., Liu, H., et al. (2014). Structural basis for hijacking CBF-beta and CUL5 E3 ligase complex by HIV-1 Vif. Nature 505, 229-233. doi: 10.1038/nature12884
84. Hache, G., Abbink, T. E., Berkhout, B., and Harris, R. S. (2009). Optimal translation initiation enables Vif-deficient human immunodeficiency virus type 1 to escape restriction by APOBEC3G. J. Virol. 83, 5956-5960. doi: 10.1128/JVI.00045-09
85. Hache, G., Liddament, M. T., and Harris, R. S. (2005). The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 280, 10920-10924. doi: 10.1074/jbc.M500382200
86. Hache, G., Shindo, K., Albin, J. S., and Harris, R. S. (2008). Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Curr. Biol. 18, 819-824. doi: 10.1016/j.cub.2008.04.073
87. Halford, S. E., and Marko, J. F. (2004). How do site-specific DNA-binding proteins find their targets? Nucleic Acids Res. 32, 3040-3052. doi: 10.1093/nar/gkh624
88. Hancks, D. C., and Kazazian, H. H. Jr. (2012). Active human retrotransposons: variation and disease. Curr. Opin. Genet. Dev. 22, 191-203. doi: 10.1016/j.gde.2012.02.006
89. Harari, A., Ooms, M., Mulder, L. C., and Simon, V. (2009). Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J. Virol. 83, 295-303. doi: 10.1128/JVI.01665-08
90. Harris, R. S. (2008). Enhancing immunity to HIV through APOBEC. Nat. Biotechnol. 26, 1089-1090. doi: 10.1038/nbt1008-1089
91. Harris, R. S., Bishop, K. N., Sheehy, A. M., Craig, H. M., Petersen-Mahrt, S. K., Watt, I. N., et al. (2003). DNA deamination mediates innate immunity to retroviral infection. Cell 113, 803-809. doi: 10.1016/S0092-8674(03)00423-9
92. Harris, R. S., Hultquist, J. F., and Evans, D. T. (2012). The restriction factors of human immunodeficiency virus. J. Biol. Chem. 287, 40875-40883. doi: 10.1074/jbc.R112.416925
93. He, Z., Zhang, W., Chen, G., Xu, R., and Yu, X. F. (2008). Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J. Mol. Biol. 381, 1000-1011. doi: 10.1016/j.jmb.2008.06.061
94. Henriet, S., Sinck, L., Bec, G., Gorelick, R. J., Marquet, R., and Paillart, J. C. (2007). Vif is a RNA chaperone that could temporally regulate RNA dimerization and the early steps of HIV-1 reverse transcription. Nucleic Acids Res. 35, 5141-5153. doi: 10.1093/nar/gkm542
95. Hoglund, S., Ohagen, A., Lawrence, K., and Gabuzda, D. (1994). Role of vif during packing of the core of HIV-1. Virology 201, 349-355. doi: 10.1006/viro.1994.1300
96. Holmes, R. K., Koning, F. A., Bishop, K. N., and Malim, M. H. (2007). APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem. 282, 2587-2595. doi: 10.1074/jbc.M607298200
97. Hu, C., Saenz, D. T., Fadel, H. J., Walker, W., Peretz, M., and Poeschla, E. M. (2010). The HIV-1 central polypurine tract functions as a second line of defense against APOBEC3G/F. J. Virol. 84, 11981-11993. doi: 10.1128/JVI.00723-10
98. Hultquist, J. F., Binka, M., Larue, R. S., Simon, V., and Harris, R. S. (2012). Vif proteins of human and simian immunodeficiency viruses require cellular CBFbeta to degrade APOBEC3 restriction factors. J. Virol. 86, 2874-2877. doi: 10.1128/JVI.06950-11
99. Hultquist, J. F., and Harris, R. S. (2009). Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS. Future Virol. 4, 605. doi: 10.2217/fvl.09.59
100. Hultquist, J. F., Lengyel, J. A., Refsland, E. W., Larue, R. S., Lackey, L., Brown, W. L., et al. (2011). Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85, 11220-11234. doi: 10.1128/JVI.05238-11
101. Huthoff, H., Autore, F., Gallois-Montbrun, S., Fraternali, F., and Malim, M. H. (2009). RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog. 5:e1000330. doi: 10.1371/journal.ppat.1000330
102. Huthoff, H., and Malim, M. H. (2007). Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J. Virol. 81, 3807-3815. doi: 10.1128/JVI.02795-06
103. Iwai, K., Yamanaka, K., Kamura, T., Minato, N., Conaway, R. C., Conaway, J. W., et al. (1999). Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc. Natl. Acad. Sci. U.S.A. 96, 12436-12441. doi: 10.1073/pnas.96.22.12436
104. Iwatani, Y., Chan, D. S., Wang, F., Maynard, K. S., Sugiura, W., Gronenborn, A. M., et al. (2007). Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 35, 7096-7108. doi: 10.1093/nar/gkm750
105. Iwatani, Y., Takeuchi, H., Strebel, K., and Levin, J. G. (2006). Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J. Virol. 80, 5992-6002. doi: 10.1128/JVI.02680-05
106. Jager, S., Cimermancic, P., Gulbahce, N., Johnson, J. R., Mcgovern, K. E., Clarke, S. C., et al. (2012). Global landscape of HIV-human protein complexes. Nature 481, 365-370. doi: 10.1038/nature10719
107. Jarmuz, A., Chester, A., Bayliss, J., Gisbourne, J., Dunham, I., Scott, J., et al. (2002). An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79, 285-296. doi: 10.1006/geno.2002.6718
108. Jern, P., and Coffin, J. M. (2008). Host-retrovirus arms race: trimming the budget. Cell Host Microbe 4, 196-197. doi: 10.1016/j.chom.2008.08.008
109. Jern, P., Russell, R. A., Pathak, V. K., and Coffin, J. M. (2009). Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog. 5:e1000367. doi: 10.1371/journal.ppat.1000367
110. Jin, X., Brooks, A., Chen, H., Bennett, R., Reichman, R., and Smith, H. (2005). APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J. Virol. 79, 11513-11516. doi: 10.1128/JVI.79.17.11513-11516.2005
111. Jonsson, S. R., Hache, G., Stenglein, M. D., Fahrenkrug, S. C., Andresdottir, V., and Harris, R. S. (2006). Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins. Nucleic Acids Res. 34, 5683-5694. doi: 10.1093/nar/gkl721
112. Kaiser, S. M., and Emerman, M. (2006). Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J. Virol. 80, 875-882. doi: 10.1128/JVI.80.2.875-882.2006
113. Kamura, T., Maenaka, K., Kotoshiba, S., Matsumoto, M., Kohda, D., Conaway, R. C., et al. (2004). VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev. 18, 3055-3065. doi: 10.1101/gad.1252404
114. Kamura, T., Sato, S., Haque, D., Liu, L., Kaelin, W. G. Jr., et al. (1998). The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 12, 3872-3881. doi: 10.1101/gad.12.24.3872
115. Kao, S., Khan, M. A., Miyagi, E., Plishka, R., Buckler-White, A., and Strebel, K. (2003). The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J. Virol. 77, 11398-11407. doi: 10.1128/JVI.77.21.11398-11407.2003
116. Khan, M. A., Goila-Gaur, R., Opi, S., Miyagi, E., Takeuchi, H., Kao, S., et al. (2007). Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions. Retrovirology 4, 48. doi: 10.1186/1742-4690-4-48
117. Khatua, A. K., Taylor, H. E., Hildreth, J. E., and Popik, W. (2010). Inhibition of LINE-1 and Alu retrotransposition by exosomes encapsidating APOBEC3G and APOBEC3F. Virology 400, 68-75. doi: 10.1016/j.virol.2010.01.021
118. Kim, D. Y., Kwon, E., Hartley, P. D., Crosby, D. C., Mann, S., Krogan, N. J., et al. (2013). CBFbeta stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression. Mol. Cell. 49, 632-644. doi: 10.1016/j.molcel.2012.12.012
119. Kim, E. Y., Bhattacharya, T., Kunstman, K., Swantek, P., Koning, F. A., Malim, M. H., et al. (2010). Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J. Virol. 84, 10402-10405. doi: 10.1128/JVI.01223-10
120. Kitamura, S., Ode, H., and Iwatani, Y. (2011). Structural features of Antiviral APOBEC3 proteins are linked to their functional activities. Front. Microbiol. 2:258. doi: 10.3389/fmicb.2011.00258
121. Kitamura, S., Ode, H., Nakashima, M., Imahashi, M., Naganawa, Y., Kurosawa, T., et al. (2012). The APOBEC3C crystal structure and the interface for HIV-1 Vif binding. Nat. Struct. Mol. Biol. 19, 1005-1010. doi: 10.1038/nsmb.2378
122. Kobayashi, M., Takaori-Kondo, A., Miyauchi, Y., Iwai, K., and Uchiyama, T. (2005). Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function. J. Biol. Chem. 280, 18573-18578. doi: 10.1074/jbc.C500082200
123. Kobayashi, T., Koizumi, Y., Takeuchi, J. S., Misawa, N., Kimura, Y., Morita, S., et al. (2014). Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation. J. Virol. 88, 5881-5887. doi: 10.1128/JVI.00062-14
124. Kock, J., and Blum, H. E. (2008). Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H. J. Gen. Virol. 89, 1184-1191. doi: 10.1099/vir.0.83507-0
125. Kohli, R. M., Abrams, S. R., Gajula, K. S., Maul, R. W., Gearhart, P. J., and Stivers, J. T. (2009). A portable hot spot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase. J. Biol. Chem. 284, 22898-22904. doi: 10.1074/jbc.M109.025536
126. Koning, F. A., Goujon, C., Bauby, H., and Malim, M. H. (2011). Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages. J. Virol. 85, 13448-13452. doi: 10.1128/JVI.00775-11
127. Koning, F. A., Newman, E. N., Kim, E. Y., Kunstman, K. J., Wolinsky, S. M., and Malim, M. H. (2009). Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J. Virol. 83, 9474-9485. doi: 10.1128/JVI.01089-09
128. Koyama, T., Arias, J. F., Iwabu, Y., Yokoyama, M., Fujita, H., Sato, H., et al. (2013). APOBEC3G oligomerization is associated with the inhibition of both Alu and LINE-1 retrotransposition. PLoS ONE 8:e84228. doi: 10.1371/journal.pone.0084228
129. Kozak, S. L., Marin, M., Rose, K. M., Bystrom, C., and Kabat, D. (2006). The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J. Biol. Chem. 281, 29105-29119. doi: 10.1074/jbc.M601901200
130. Land, A. M., Ball, T. B., Luo, M., Pilon, R., Sandstrom, P., Embree, J. E., et al. (2008). Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J. Virol. 82, 8172-8182. doi: 10.1128/JVI.01115-08
131. Langlois, M. A., Beale, R. C., Conticello, S. G., and Neuberger, M. S. (2005). Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res. 33, 1913-1923. doi: 10.1093/nar/gki343
132. LaRue, R. S., Andresdottir, V., Blanchard, Y., Conticello, S. G., Derse, D., Emerman, M., et al. (2009). Guidelines for naming nonprimate APOBEC3 genes and proteins. J. Virol. 83, 494-497. doi: 10.1128/JVI.01976-08
133. LaRue, R. S., Jonsson, S. R., Silverstein, K. A., Lajoie, M., Bertrand, D., El-Mabrouk, N., et al. (2008). The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol. Biol. 9:104. doi: 10.1186/1471-2199-9-104
134. Lavens, D., Peelman, F., Van Der Heyden, J., Uyttendaele, I., Catteeuw, D., Verhee, A., et al. (2010). Definition of the interacting interfaces of Apobec3G and HIV-1 Vif using MAPPIT mutagenesis analysis. Nucleic Acids Res. 38, 1902-1912. doi: 10.1093/nar/gkp1154
135. Letko, M., Silvestri, G., Hahn, B. H., Bibollet-Ruche, F., Gokcumen, O., Simon, V., et al. (2013). Vif proteins from diverse primate lentiviral lineages use the same binding site in APOBEC3G. J. Virol. 87, 11861-11871. doi: 10.1128/JVI.01944-13
136. Li, J., Chen, Y., Li, M., Carpenter, M. A., Mcdougle, R. M., Luengas, E. M., et al. (2014). APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells. J. Mol. Biol. 426, 1296-1307. doi: 10.1016/j.jmb.2013.12.014
137. Li, M., Shandilya, S. M., Carpenter, M. A., Rathore, A., Brown, W. L., Perkins, A. L., et al. (2012). First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem. Biol. 7, 506-517. doi: 10.1021/cb200440y
138. Li, M. M., and Emerman, M. (2011). Polymorphism in human APOBEC3H affects a phenotype dominant for subcellular localization and antiviral activity. J. Virol. 85, 8197-8207. doi: 10.1128/JVI.00624-11
139. Li, M. M., Wu, L. I., and Emerman, M. (2010). The range of human APOBEC3H sensitivity to lentiviral Vif proteins. J. Virol. 84, 88-95. doi: 10.1128/JVI.01344-09
140. Li, Y., Kappes, J. C., Conway, J. A., Price, R. W., Shaw, G. M., and Hahn, B. H. (1991). Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes. J. Virol. 65, 3973-3985.
141. Liddament, M. T., Brown, W. L., Schumacher, A. J., and Harris, R. S. (2004). APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14, 1385-1391. doi: 10.1016/j.cub.2004.06.050
142. Liu, S., Harada, B. T., Miller, J. T., Le Grice, S. F., and Zhuang, X. (2010). Initiation complex dynamics direct the transitions between distinct phases of early HIV reverse transcription. Nat. Struct. Mol. Biol. 17, 1453-1460. doi: 10.1038/nsmb.1937
143. Logue, E. C., Bloch, N., Dhuey, E., Zhang, R., Cao, P., Herate, C., et al. (2014). A DNA sequence recognition loop on APOBEC3A controls substrate Specificity. PLoS ONE 9:e97062. doi: 10.1371/journal.pone.0097062
144. Love, R. P., Xu, H., and Chelico, L. (2012). Biochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A. J. Biol. Chem. 287, 30812-30822. doi: 10.1074/jbc.M112.393181
145. Lucifora, J., Xia, Y., Reisinger, F., Zhang, K., Stadler, D., Cheng, X., et al. (2014). Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343, 1221-1228. doi: 10.1126/science.1243462
146. Luo, K., Wang, T., Liu, B., Tian, C., Xiao, Z., Kappes, J., et al. (2007). Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 81, 7238-7248. doi: 10.1128/JVI.02584-06
147. Luo, K., Xiao, Z., Ehrlich, E., Yu, Y., Liu, B., Zheng, S., et al. (2005). Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc. Natl. Acad. Sci. U.S.A. 102, 11444-11449. doi: 10.1073/pnas.0502440102
148. MacDuff, D. A., Demorest, Z. L., and Harris, R. S. (2009). AID can restrict L1 retrotransposition suggesting a dual role in innate and adaptive immunity. Nucleic Acids Res. 37, 1854-1867. doi: 10.1093/nar/gkp030
149. Madani, N., and Kabat, D. (1998). An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J. Virol. 72, 10251-10255.
150. Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L., and Trono, D. (2003). Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99-103. doi: 10.1038/nature01709
151. Mangeat, B., Turelli, P., Liao, S., and Trono, D. (2004). A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J. Biol. Chem. 279, 14481-14483. doi: 10.1074/jbc.C400060200
152. Mariani, R., Chen, D., Schrofelbauer, B., Navarro, F., Konig, R., Bollman, B., et al. (2003). Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114, 21-31. doi: 10.1016/S0092-8674(03)00515-4
153. Marin, M., Golem, S., Rose, K. M., Kozak, S. L., and Kabat, D. (2008). Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism. J. Virol. 82, 987-998. doi: 10.1128/JVI.01078-07
154. Marin, M., Rose, K. M., Kozak, S. L., and Kabat, D. (2003). HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9, 1398-1403. doi: 10.1038/nm946
155. Matsui, M., Shindo, K., Izumi, T., Io, K., Shinohara, M., Komano, J., et al. (2014a). Small molecules that inhibit Vif-induced degradation of APOBEC3G. Virol. J. 11, 122. doi: 10.1186/1743-422X-11-122
156. Matsui, Y., Shindo, K., Nagata, K., Io, K., Tada, K., Iwai, F., et al. (2014b). Defining HIV-1 Vif residues that interact with CBFbeta by site-directed mutagenesis. Virology 449, 82-87. doi: 10.1016/j.virol.2013.11.004
157. Mbisa, J. L., Barr, R., Thomas, J. A., Vandegraaff, N., Dorweiler, I. J., Svarovskaia, E. S., et al. (2007). Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 81, 7099-7110. doi: 10.1128/JVI.00272-07
158. Mbisa, J. L., Bu, W., and Pathak, V. K. (2010). APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms. J. Virol. 84, 5250-5259. doi: 10.1128/JVI.02358-09
159. Mehle, A., Goncalves, J., Santa-Marta, M., Mcpike, M., and Gabuzda, D. (2004). Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 18, 2861-2866. doi: 10.1101/gad.1249904
160. Mehle, A., Wilson, H., Zhang, C., Brazier, A. J., Mcpike, M., Pery, E., et al. (2007). Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J. Virol. 81, 13235-13241. doi: 10.1128/JVI.00204-07
161. Mercenne, G., Bernacchi, S., Richer, D., Bec, G., Henriet, S., Paillart, J. C., et al. (2010). HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation. Nucleic Acids Res. 38, 633-646. doi: 10.1093/nar/gkp1009
162. Miyagi, E., Brown, C. R., Opi, S., Khan, M., Goila-Gaur, R., Kao, S., et al. (2010). Stably expressed APOBEC3F has negligible antiviral activity. J. Virol. 84, 11067-11075. doi: 10.1128/JVI.01249-10
163. Miyagi, E., Opi, S., Takeuchi, H., Khan, M., Goila-Gaur, R., Kao, S., et al. (2007). Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J. Virol. 81, 13346-13353. doi: 10.1128/JVI.01361-07
164. Mohammed, I., Parai, M. K., Jiang, X., Sharova, N., Singh, G., Stevenson, M., et al. (2012). SAR and lead optimization of an HIV-1 Vif-APOBEC3G axis inhibitor. ACS Med. Chem. Lett. 3, 465-469. doi: 10.1021/ml300037k
165. Monajemi, M., Woodworth, C. F., Zipperlen, K., Gallant, M., Grant, M. D., and Larijani, M. (2014). Positioning of APOBEC3G/F mutational hotspots in the human immunodeficiency virus genome favors reduced recognition by CD8+ T cells. PLoS ONE 9:e93428. doi: 10.1371/journal.pone.0093428
166. Mulder, L. C., Harari, A., and Simon, V. (2008). Cytidine deamination induced HIV-1 drug resistance. Proc. Natl. Acad. Sci. U.S.A. 105, 5501-5506. doi: 10.1073/pnas.0710190105
167. Mulder, L. C., Ooms, M., Majdak, S., Smedresman, J., Linscheid, C., Harari, A., et al. (2010). Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes. J. Virol. 84, 9613-9617. doi: 10.1128/JVI.02630-09
168. Munk, C., Willemsen, A., and Bravo, I. G. (2012). An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. BMC Evol. Biol. 12:71. doi: 10.1186/1471-2148-12-71
169. Nathans, R., Cao, H., Sharova, N., Ali, A., Sharkey, M., Stranska, R., et al. (2008). Small-molecule inhibition of HIV-1 Vif. Nat. Biotechnol. 26, 1187-1192. doi: 10.1038/nbt.1496
170. Navarro, F., Bollman, B., Chen, H., Konig, R., Yu, Q., Chiles, K., et al. (2005). Complementary function of the two catalytic domains of APOBEC3G. Virology 333, 374-386. doi: 10.1016/j.virol.2005.01.011
171. Newman, E. N., Holmes, R. K., Craig, H. M., Klein, K. C., Lingappa, J. R., Malim, M. H., et al. (2005). Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15, 166-170. doi: 10.1016/j.cub.2004.12.068
172. Nowarski, R., Britan-Rosich, E., Shiloach, T., and Kotler, M. (2008). Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase. Nat. Struct. Mol. Biol. 15, 1059-1066. doi: 10.1038/nsmb.1495
173. Nowotny, B., Schneider, T., Pradel, G., Schirmeister, T., Rethwilm, A., and Kirschner, M. (2010). Inducible APOBEC3G-Vif double stable cell line as a high-throughput screening platform to identify antiviral compounds. Antimicrob. Agents Chemother. 54, 78-87. doi: 10.1128/AAC.00775-09
174. OhAinle, M., Kerns, J. A., Li, M. M., Malik, H. S., and Emerman, M. (2008). Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 4, 249-259. doi: 10.1016/j.chom.2008.07.005
175. OhAinle, M., Kerns, J. A., Malik, H. S., and Emerman, M. (2006). Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J. Virol. 80, 3853-3862. doi: 10.1128/JVI.80.8.3853-3862.2006
176. Olson, M. E., Li, M., Harris, R. S., and Harki, D. A. (2013). Small-molecule APOBEC3G DNA cytosine deaminase inhibitors based on a 4-amino-1, 2, 4-triazole-3-thiol scaffold. ChemMedChem 8, 112-117. doi: 10.1002/cmdc.201200411
177. Ooms, M., Brayton, B., Letko, M., Maio, S. M., Pilcher, C. D., Hecht, F. M., et al. (2013a). HIV-1 Vif adaptation to human APOBEC3H haplotypes. Cell Host Microbe 14, 411-421. doi: 10.1016/j.chom.2013.09.006
178. Ooms, M., Letko, M., Binka, M., and Simon, V. (2013b). The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif. PLoS ONE 8:e57744. doi: 10.1371/journal.pone.0057744
179. Ooms, M., Majdak, S., Seibert, C. W., Harari, A., and Simon, V. (2010). The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity. J. Virol. 84, 7961-7969. doi: 10.1128/JVI.00754-10
180. Opi, S., Kao, S., Goila-Gaur, R., Khan, M. A., Miyagi, E., Takeuchi, H., et al. (2007). Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J. Virol. 81, 8236-8246. doi: 10.1128/JVI.02694-06
181. Pace, C., Keller, J., Nolan, D., James, I., Gaudieri, S., Moore, C., et al. (2006). Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J. Virol. 80, 9259-9269. doi: 10.1128/JVI.00888-06
182. Pak, V., Heidecker, G., Pathak, V. K., and Derse, D. (2011). The role of amino-terminal sequences in cellular localization and antiviral activity of APOBEC3B. J. Virol. 85, 8538-8547. doi: 10.1128/JVI.02645-10
183. Pathak, V. K., and Temin, H. M. (1990). Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: substitutions, frameshifts, and hypermutations. Proc. Natl. Acad. Sci. U.S.A. 87, 6019-6023. doi: 10.1073/pnas.87.16.6019
184. Pery, E., Rajendran, K. S., Brazier, A. J., and Gabuzda, D. (2009). Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J. Virol. 83, 2374-2381. doi: 10.1128/JVI.01898-08
185. Rahm, N., and Telenti, A. (2012). The role of tripartite motif family members in mediating susceptibility to HIV-1 infection. Curr. Opin. HIV AIDS 7, 180-186. doi: 10.1097/COH.0b013e32835048e1
186. Rathore, A., Carpenter, M. A., Demir, O., Ikeda, T., Li, M., Shaban, N. M., et al. (2013). The local dinucleotide preference of APOBEC3G can be altered from 5'-CC to 5'-TC by a single amino acid substitution. J. Mol. Biol. 425, 4442-4454. doi: 10.1016/j.jmb.2013.07.040
187. Refsland, E. W., Hultquist, J. F., and Harris, R. S. (2012). Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog. 8:e1002800. doi: 10.1371/journal.ppat.1002800
188. Refsland, E. W., Stenglein, M. D., Shindo, K., Albin, J. S., Brown, W. L., and Harris, R. S. (2010). Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38, 4274-4284. doi: 10.1093/nar/gkq174
189. Richardson, S. R., Narvaiza, I., Planegger, R. A., Weitzman, M. D., and Moran, J. V. (2014). APOBEC3A deaminates transiently exposed single-strand DNA during LINE-1 retrotransposition. Elife 3, e02008. doi: 10.7554/eLife.02008
190. Russell, R. A., Moore, M. D., Hu, W. S., and Pathak, V. K. (2009a). APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology 6, 16. doi: 10.1186/1742-4690-6-16
191. Russell, R. A., Smith, J., Barr, R., Bhattacharyya, D., and Pathak, V. K. (2009b). Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J. Virol. 83, 1992-2003. doi: 10.1128/JVI.01621-08
192. Russell, R. A., and Pathak, V. K. (2007). Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 81, 8201-8210. doi: 10.1128/JVI.00395-07
193. Sadler, H. A., Stenglein, M. D., Harris, R. S., and Mansky, L. M. (2010). APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J. Virol. 84, 7396-7404. doi: 10.1128/JVI.00056-10
194. Sakai, H., Shibata, R., Sakuragi, J., Sakuragi, S., Kawamura, M., and Adachi, A. (1993). Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J. Virol. 67, 1663-1666.
195. Santa-Marta, M., Da Silva, F. A., Fonseca, A. M., and Goncalves, J. (2005). HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. J. Biol. Chem. 280, 8765-8775. doi: 10.1074/jbc.M409309200
196. Schrofelbauer, B., Chen, D., and Landau, N. R. (2004). A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc. Natl. Acad. Sci. U.S.A. 101, 3927-3932. doi: 10.1073/pnas.0307132101
197. Schumacher, A. J., Hache, G., Macduff, D. A., Brown, W. L., and Harris, R. S. (2008). The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J. Virol. 82, 2652-2660. doi: 10.1128/JVI.02391-07
198. Senavirathne, G., Jaszczur, M., Auerbach, P. A., Upton, T. G., Chelico, L., Goodman, M. F., et al. (2012). Single-stranded DNA scanning and deamination by APOBEC3G cytidine deaminase at single molecule resolution. J. Biol. Chem. 287, 15826-15835. doi: 10.1074/jbc.M112.342790
199. Shaw, G. M., and Hunter, E. (2012). HIV transmission. Cold Spring Harb. Perspect. Med. 2. doi: 10.1101/cshperspect.a006965
200. Sheehy, A. M., Gaddis, N. C., Choi, J. D., and Malim, M. H. (2002). Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650. doi: 10.1038/nature00939
201. Sheehy, A. M., Gaddis, N. C., and Malim, M. H. (2003). The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9, 1404-1407. doi: 10.1038/nm945
202. Shlyakhtenko, L. S., Lushnikov, A. J., Li, M., Harris, R. S., and Lyubchenko, Y. L. (2014). Interaction of APOBEC3A with DNA Assessed by Atomic Force Microscopy. PLoS ONE 9:e99354. doi: 10.1371/journal.pone.0099354
203. Shlyakhtenko, L. S., Lushnikov, A. Y., Li, M., Lackey, L., Harris, R. S., and Lyubchenko, Y. L. (2011). Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G. J. Biol. Chem. 286, 3387-3395. doi: 10.1074/jbc.M110.195685
204. Shlyakhtenko, L. S., Lushnikov, A. Y., Miyagi, A., Li, M., Harris, R. S., and Lyubchenko, Y. L. (2012). Nanoscale structure and dynamics of ABOBEC3G complexes with single-stranded DNA. Biochemistry 51, 6432-6440. doi: 10.1021/bi300733d
205. Simon, J. H., Gaddis, N. C., Fouchier, R. A., and Malim, M. H. (1998). Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat. Med. 4, 1397-1400. doi: 10.1038/3987
206. Simon, V., Zennou, V., Murray, D., Huang, Y., Ho, D. D., and Bieniasz, P. D. (2005). Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1:e6. doi: 10.1371/journal.ppat.0010006
207. Siu, K. K., Sultana, A., Azimi, F. C., and Lee, J. E. (2013). Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F. Nat. Commun. 4, 2593. doi: 10.1038/ncomms3593
208. Smith, J. L., and Pathak, V. K. (2010). Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif. J. Virol. 84, 12599-12608. doi: 10.1128/JVI.01437-10
209. Song, C., Sutton, L., Johnson, M. E., D'Aquila, R. T., and Donahue, J. P. (2012). Signals in APOBEC3F N-terminal and C-terminal deaminase domains each contribute to encapsidation in HIV-1 virions and are both required for HIV-1 restriction. J. Biol. Chem. 287, 16965-16974. doi: 10.1074/jbc.M111.310839
210. Soros, V. B., Yonemoto, W., and Greene, W. C. (2007). Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog. 3:e15. doi: 10.1371/journal.ppat.0030015
211. Stanley, B. J., Ehrlich, E. S., Short, L., Yu, Y., Xiao, Z., Yu, X. F., et al. (2008). Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J. Virol. 82, 8656-8663. doi: 10.1128/JVI.00767-08
212. Stopak, K., De Noronha, C., Yonemoto, W., and Greene, W. C. (2003). HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell. 12, 591-601. doi: 10.1016/S1097-2765(03)00353-8
213. Stopak, K. S., Chiu, Y. L., Kropp, J., Grant, R. M., and Greene, W. C. (2007). Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J. Biol. Chem. 282, 3539-3546. doi: 10.1074/jbc.M610138200
214. Strebel, K., Daugherty, D., Clouse, K., Cohen, D., Folks, T., and Martin, M. A. (1987). The HIV 'A' (sor) gene product is essential for virus infectivity. Nature 328, 728-730. doi: 10.1038/328728a0
215. Strebel, K., and Khan, M. A. (2008). APOBEC3G encapsidation into HIV-1 virions: which RNA is it? Retrovirology 5, 55. doi: 10.1186/1742-4690-5-55
216. Suspene, R., Rusniok, C., Vartanian, J. P., and Wain-Hobson, S. (2006). Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res. 34, 4677-4684. doi: 10.1093/nar/gkl555
217. Suspene, R., Sommer, P., Henry, M., Ferris, S., Guetard, D., Pochet, S., et al. (2004). APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res. 32, 2421-2429. doi: 10.1093/nar/gkh554
218. Svarovskaia, E. S., Xu, H., Mbisa, J. L., Barr, R., Gorelick, R. J., Ono, A., et al. (2004). Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol. Chem. 279, 35822-35828. doi: 10.1074/jbc.M405761200
219. Tan, L., Sarkis, P. T., Wang, T., Tian, C., and Yu, X. F. (2009). Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEB J. 23, 279-287. doi: 10.1096/fj.07-088781
220. Tian, C., Yu, X., Zhang, W., Wang, T., Xu, R., and Yu, X. F. (2006). Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J. Virol. 80, 3112-3115. doi: 10.1128/JVI.80.6.3112-3115.2006
221. Vartanian, J. P., Henry, M., and Wain-Hobson, S. (2002). Sustained G→A hypermutation during reverse transcription of an entire human immunodeficiency virus type 1 strain Vau group O genome. J. Gen. Virol. 83, 801-805.
222. Vartanian, J. P., Meyerhans, A., Asjo, B., and Wain-Hobson, S. (1991). Selection, recombination, and G→A hypermutation of human immunodeficiency virus type 1 genomes. J. Virol. 65, 1779-1788.
223. Vazquez-Perez, J. A., Ormsby, C. E., Hernandez-Juan, R., Torres, K. J., and Reyes-Teran, G. (2009). APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression. Retrovirology 6, 23. doi: 10.1186/1742-4690-6-23
224. von Hippel, P. H., and Berg, O. G. (1989). Facilitated target location in biological systems. J. Biol. Chem. 264, 675-678.
225. von Schwedler, U., Song, J., Aiken, C., and Trono, D. (1993). Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J. Virol. 67, 4945-4955.
226. Wang, H., Liu, B., Liu, X., Li, Z., Yu, X. F., and Zhang, W. (2014). Identification of HIV-1 Vif regions required for CBF-beta Interaction and APOBEC3 suppression. PLoS ONE 9:e95738. doi: 10.1371/journal.pone.0095738
227. Wang, J., Reuschel, E. L., Shackelford, J. M., Jeang, L., Shivers, D. K., Diehl, J. A., et al. (2011a). HIV-1 Vif promotes the G(1)- to S-phase cell-cycle transition. Blood 117, 1260-1269. doi: 10.1182/blood-2010-06-289215
228. Wang, X., Abudu, A., Son, S., Dang, Y., Venta, P. J., and Zheng, Y. H. (2011b). Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity. J. Virol. 85, 3142-3152. doi: 10.1128/JVI.02049-10
229. Wang, T., Tian, C., Zhang, W., Luo, K., Sarkis, P. T., Yu, L., et al. (2007). 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J. Virol. 81, 13112-13124. doi: 10.1128/JVI.00892-07
230. Wang, T., Tian, C., Zhang, W., Sarkis, P. T., and Yu, X. F. (2008). Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging. J. Mol. Biol. 375, 1098-1112. doi: 10.1016/j.jmb.2007.11.017
231. Wang, X., Ao, Z., Chen, L., Kobinger, G., Peng, J., and Yao, X. (2012). The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication. J. Virol. 86, 3777-3786. doi: 10.1128/JVI.06594-11
232. Wang, X., Zhang, H., Lv, M., Zuo, T., Wu, H., Wang, J., et al. (2013). Interactions between HIV-1 Vif and human ElonginB-ElonginC are important for CBF-beta binding to Vif. Retrovirology 10, 94. doi: 10.1186/1742-4690-10-94
233. Wichroski, M. J., Robb, G. B., and Rana, T. M. (2006). Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog. 2:e41. doi: 10.1371/journal.ppat.0020041
234. Wiegand, H. L., Doehle, B. P., Bogerd, H. P., and Cullen, B. R. (2004). A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23, 2451-2458. doi: 10.1038/sj.emboj.7600246
235. Xiao, Z., Ehrlich, E., Luo, K., Xiong, Y., and Yu, X. F. (2007). Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J. 21, 217-222. doi: 10.1096/fj.06-6773com
236. Xiao, Z., Ehrlich, E., Yu, Y., Luo, K., Wang, T., Tian, C., et al. (2006). Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 349, 290-299. doi: 10.1016/j.virol.2006.02.002
237. Xu, H., Chertova, E., Chen, J., Ott, D. E., Roser, J. D., Hu, W. S., et al. (2007). Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology 360, 247-256. doi: 10.1016/j.virol.2006.10.036
238. Xu, H., Svarovskaia, E. S., Barr, R., Zhang, Y., Khan, M. A., Strebel, K., et al. (2004). A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc. Natl. Acad. Sci. U.S.A. 101, 5652-5657. doi: 10.1073/pnas.0400830101
239. Xu, H., Wang, X., and Veazey, R. S. (2013). Mucosal immunology of HIV infection. Immunol. Rev. 254, 10-33. doi: 10.1111/imr.12072
240. Yamashita, T., Kamada, K., Hatcho, K., Adachi, A., and Nomaguchi, M. (2008). Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F. Microbes Infect. 10, 1142-1149. doi: 10.1016/j.micinf.2008.06.003
241. Yang, B., Chen, K., Zhang, C., Huang, S., and Zhang, H. (2007). Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J. Biol. Chem. 282, 11667-11675. doi: 10.1074/jbc.M606864200
242. Yang, X., Goncalves, J., and Gabuzda, D. (1996). Phosphorylation of Vif and its role in HIV-1 replication. J. Biol. Chem. 271, 10121-10129. doi: 10.1074/jbc.271.17.10121
243. Yu, Q., Konig, R., Pillai, S., Chiles, K., Kearney, M., Palmer, S., et al. (2004). Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11, 435-442. doi: 10.1038/nsmb758
244. Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Mao, P., et al. (2003). Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302, 1056-1060. doi: 10.1126/science.1089591
245. Zennou, V., and Bieniasz, P. D. (2006). Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. Virology 349, 31-40. doi: 10.1016/j.virol.2005.12.035
246. Zhang, H., Yang, B., Pomerantz, R. J., Zhang, C., Arunachalam, S. C., and Gao, L. (2003). The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424, 94-98. doi: 10.1038/nature01707
247. Zhang, W., Du, J., Evans, S. L., Yu, Y., and Yu, X. F. (2012). T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481, 376-379. doi: 10.1038/nature10718
248. Zhen, A., Du, J., Zhou, X., Xiong, Y., and Yu, X. F. (2012). Reduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities. PLoS ONE 7:e38771. doi: 10.1371/journal.pone.0038771
249. Zhen, A., Wang, T., Zhao, K., Xiong, Y., and Yu, X. F. (2010). A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J. Virol. 84, 1902-1911. doi: 10.1128/JVI.01509-09
250. Zheng, Y. H., Irwin, D., Kurosu, T., Tokunaga, K., Sata, T., and Peterlin, B. M. (2004). Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78, 6073-6076. doi: 10.1128/JVI.78.11.6073-6076.2004
251. Zhou, X., Evans, S. L., Han, X., Liu, Y., and Yu, X. F. (2012). Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFbeta and CRL5 E3 ubiquitin ligase components. PLoS ONE 7:e33495. doi: 10.1371/journal.pone.0033495
252. Zuo, T., Liu, D., Lv, W., Wang, X., Wang, J., Lv, M., et al. (2012). Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC. J. Virol. 86, 5497-5507. doi: 10.1128/JVI.06957-11